CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 119 filers reported holding CYTOMX THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $872,707 | -21.2% | 676,343 | +5.0% | 0.00% | – |
| Q2 2023 | $1,107,829 | +14.2% | 644,087 | +0.3% | 0.00% | – |
| Q1 2023 | $969,885 | +100510.5% | 642,308 | +6.5% | 0.00% | – |
| Q4 2022 | $964 | -99.9% | 603,075 | +2.7% | 0.00% | – |
| Q3 2022 | $851,000 | -20.2% | 587,451 | +0.8% | 0.00% | – |
| Q2 2022 | $1,067,000 | -61.9% | 583,065 | -44.5% | 0.00% | – |
| Q1 2022 | $2,803,000 | -44.8% | 1,050,148 | -10.5% | 0.00% | -100.0% |
| Q4 2021 | $5,082,000 | -11.1% | 1,173,847 | +4.5% | 0.00% | 0.0% |
| Q3 2021 | $5,716,000 | -21.7% | 1,123,083 | -2.6% | 0.00% | 0.0% |
| Q2 2021 | $7,298,000 | -12.4% | 1,153,010 | +7.0% | 0.00% | 0.0% |
| Q1 2021 | $8,329,000 | +67.7% | 1,077,618 | +42.1% | 0.00% | 0.0% |
| Q4 2020 | $4,966,000 | -0.8% | 758,314 | +0.7% | 0.00% | 0.0% |
| Q3 2020 | $5,007,000 | -15.2% | 753,164 | +6.2% | 0.00% | 0.0% |
| Q2 2020 | $5,905,000 | +9.2% | 708,889 | +0.5% | 0.00% | 0.0% |
| Q1 2020 | $5,408,000 | -50.4% | 705,187 | -46.3% | 0.00% | 0.0% |
| Q4 2019 | $10,906,000 | +139.5% | 1,312,514 | +112.7% | 0.00% | 0.0% |
| Q3 2019 | $4,553,000 | -32.2% | 617,046 | +3.0% | 0.00% | -50.0% |
| Q2 2019 | $6,720,000 | +4.8% | 598,991 | +0.4% | 0.00% | 0.0% |
| Q1 2019 | $6,415,000 | -62.5% | 596,814 | -47.4% | 0.00% | -33.3% |
| Q4 2018 | $17,120,000 | +80.0% | 1,133,802 | +120.5% | 0.00% | 0.0% |
| Q3 2018 | $9,511,000 | +14.6% | 514,165 | +41.6% | 0.00% | 0.0% |
| Q2 2018 | $8,301,000 | -11.6% | 363,128 | +9.9% | 0.00% | 0.0% |
| Q1 2018 | $9,395,000 | +28.1% | 330,274 | -4.9% | 0.00% | +50.0% |
| Q4 2017 | $7,334,000 | +23.9% | 347,473 | +6.6% | 0.00% | 0.0% |
| Q3 2017 | $5,921,000 | +62.8% | 325,925 | +38.8% | 0.00% | +100.0% |
| Q2 2017 | $3,638,000 | +0.9% | 234,763 | +12.5% | 0.00% | 0.0% |
| Q1 2017 | $3,604,000 | +71.1% | 208,710 | +8.9% | 0.00% | 0.0% |
| Q4 2016 | $2,106,000 | -25.6% | 191,719 | +6.1% | 0.00% | 0.0% |
| Q3 2016 | $2,832,000 | +264.5% | 180,661 | +137.4% | 0.00% | – |
| Q2 2016 | $777,000 | -11.7% | 76,114 | +11.5% | 0.00% | – |
| Q1 2016 | $880,000 | -27.3% | 68,254 | +17.5% | 0.00% | -100.0% |
| Q4 2015 | $1,211,000 | – | 58,070 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
| MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
| Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
| Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
| Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
| BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
| RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
| EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
| DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
| HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |